MDPV

Methylenedioxypyrovalerone (MDPV) is a synthetic stimulant of the cathinone and pyrrolidine chemical classes that became the most pharmacologically potent and clinically significant member of the "bath salts" NPS wave of the late 2000s and early 2010s. It is structurally related to pyrovalerone — an obscure appetite suppressant developed in the 1960s — through the addition of a methylenedioxy ring, and to MDPPP (the homolog without the methylenedioxy group) and other pyrrolidine cathinones.

MDPV acts as an extremely potent norepinephrine-dopamine reuptake inhibitor, without meaningful serotonergic activity. Unlike MDMA-class cathinones, MDPV has no entactogenic component — it produces purely catecholaminergic stimulation of exceptional intensity. MDPV is substantially more potent than cocaine by weight as a DAT/NET inhibitor, and its affinity for the dopamine transporter translates directly to an intense, compulsive, cocaine-like experience with dramatically shorter duration (15–30 minutes of peak effects) that drives rapid, uncontrolled redosing.

The "bath salts" era was defined primarily by MDPV. The media and public health response to incidents involving MDPV-intoxicated individuals — the face-eating incident in Miami (later found not to involve MDPV), violent psychotic episodes, and extreme self-harm — generated intense public and legislative attention. While some individual incidents were misattributed to MDPV, the genuine pharmacological basis for the psychiatric sequelae is well-documented in clinical case series and pharmacological research: MDPV produces stimulant psychosis, extreme agitation, and compulsive use patterns that exceed those of virtually any other known research chemical stimulant.

MDPV is considered by many harm reduction professionals to be one of the most dangerous substances in the research chemical market. Its exceptional potency, extremely short peak duration that drives the redosing cycle, and documented association with severe psychiatric events place it at the apex of the cathinone risk spectrum alongside high-dose A-PVP. Its use should be approached — if at all — with extraordinary caution and comprehensive harm reduction measures.